RMTI ROCKWELL MEDICAL, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1041024 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.0%
TTM net income YoY-2.5%
TTM EPS YoY95.2%
Revenue 3-yr CAGR-3.5%
Net income 3-yr CAGR—
Margins
Gross margin18.1%
Operating margin-7.1%
Net margin-7.8%
FCF margin1.1%
EBITDA margin-4.6%
Returns
ROE-16.1%
ROA-9.9%
ROIC (approx.)-12.8%
Asset turnover1.27x
Leverage & solvency
Liabilities / assets42.0%
Debt / equity0.27x
Current ratio2.47x
Interest coverage-4.56x
Cash quality & payout
Operating cash flow / net income-0.47x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $69.26M | $101.49M |
| Cost of revenue | $57.56M | $84.00M |
| Gross profit | $11.70M | $17.48M |
| R&D expense | $0 | $19,000 |
| SG&A expense | $14.03M | $14.11M |
| Operating income | -$4.69M | $608,000 |
| Interest expense | $1.12M | $1.25M |
| Pretax income | -$5.31M | -$480,000 |
| Income tax | $0 | $0 |
| Net income | -$5.31M | -$480,000 |
| EBITDA | -$2.50M | $2.79M |
| EPS (basic) | -0.15 | -0.03 |
| EPS (diluted) | -0.15 | -0.03 |
| Weighted avg. shares (diluted) | 35.97M | 31.06M |
| Balance sheet | ||
| Cash & equivalents | $10.71M | $15.66M |
| Short-term investments | $14.29M | $5.94M |
| Receivables | $8.14M | $8.29M |
| Inventory | $3.42M | $5.78M |
| Current assets | $38.16M | $37.03M |
| PP&E, net | $4.63M | $5.79M |
| Goodwill | $921,000 | $921,000 |
| Intangibles | $9.66M | $10.21M |
| Total assets | $57.15M | $59.21M |
| Current liabilities | $9.58M | $14.09M |
| Short-term debt | $0 | — |
| Long-term debt | $8.83M | $8.47M |
| Total debt | $8.83M | $8.47M |
| Total liabilities | $20.16M | $26.62M |
| Shareholders' equity | $36.98M | $32.59M |
| Net debt | -$1.89M | -$7.19M |
| Shares outstanding | 3.94M | 34.06M |
| Cash flow statement | ||
| Operating cash flow | -$659,000 | $4.20M |
| Capital expenditure | $542,000 | $1.01M |
| Free cash flow | -$1.20M | $3.19M |
| Investing cash flow | -$8.54M | -$4.87M |
| Financing cash flow | $4.25M | $7.35M |
| Depreciation & amortization | $2.19M | $2.18M |
| Stock-based compensation | $1.82M | $1.29M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.